Literature DB >> 15910305

Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient.

Umberto Baccarani1, Gian Luigi Adani, Andrea Sanna, Claudio Avellini, Mauricio Sainz-Barriga, Dario Lorenzin, Domenico Montanaro, Daniele Gasparini, Andrea Risaliti, Annibale Donini, Fabrizio Bresadola.   

Abstract

Hepatocytes transplantation is viewed as a possible alternative or as a bridge therapy to liver transplantation for patients affected by acute or chronic liver disorders. Very few data regarding complications of hepatocytes transplantation is available from the literature. Herein we report for the first time a case of portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient. A patient affected by acute graft dysfunction, not eligible for retransplantation, underwent intraportal infusion of 2 billion viable cryopreserved ABO identical human allogenic hepatocytes over a period of 5 h. Hepatocytes were transplanted at a concentration of 14 million/ml for a total infused volume of 280 ml. Doppler portal vein ultrasound and intraportal pressure were monitored during cell infusion. The procedure was complicated, 8 h after termination, by the development of portal vein thrombosis with liver failure and death of the patient. Autopsy showed occlusive thrombosis of the intrahepatic portal vein branches; cells or large aggregates of epithelial elements (polyclonal CEA positive), suggestive for transplanted hepatocytes, were co-localized inside the thrombus.

Entities:  

Mesh:

Year:  2005        PMID: 15910305     DOI: 10.1111/j.1432-2277.2005.00127.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  18 in total

1.  Improvement of Infusion Process in Cell Transplantation: Effect of Shear Stress on Hepatocyte Viability Under Horizontal and Vertical Syringe Orientation.

Authors:  Sandi Sufiandi; Hiromichi Obara; Shin Enosawa; Huai-Che Hsu; Naoto Matsuno; Hiroshi Mizunuma
Journal:  Cell Med       Date:  2014-12-12

2.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

3.  Hepatocyte transplantation.

Authors:  Ragai R Mitry; Robin D Hughes; Anil Dhawan
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 4.  Hepatocyte transplantation program: Lessons learned and future strategies.

Authors:  Eugenia Pareja Ibars; Miriam Cortes; Laia Tolosa; Maria José Gómez-Lechón; Slivia López; José Vicente Castell; José Mir
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 5.  Liver cell transplantation for the treatment of inborn errors of metabolism.

Authors:  J Meyburg; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

6.  Hepatocyte tissue factor activates the coagulation cascade in mice.

Authors:  Bradley P Sullivan; Anna K Kopec; Nikita Joshi; Holly Cline; Juliette A Brown; Stephanie C Bishop; Karen M Kassel; Cheryl Rockwell; Nigel Mackman; James P Luyendyk
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

7.  Clinical applications of hepatocyte transplantation.

Authors:  Giada Pietrosi; Giovanni Battista Vizzini; Salvatore Gruttadauria; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

8.  Portocaval shunt for hepatocyte package: challenging application of small intestinal graft in animal models.

Authors:  Junji Iwasaki; Toshiyuki Hata; Shinji Uemoto; Yasuhiro Fujimoto; Hiroyuki Kanazawa; Takumi Teratani; Shuji Hishikawa; Eiji Kobayashi
Journal:  Organogenesis       Date:  2013-08-08       Impact factor: 2.500

9.  The use of cellular technologies in treatment of liver pathologies.

Authors:  O S Petrakova; E S Chernioglo; V V Terskikh; E N Kalistratova; A V Vasiliev
Journal:  Acta Naturae       Date:  2012-07       Impact factor: 1.845

10.  Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity.

Authors:  Xavier Stephenne; Emanuele Nicastro; Stephane Eeckhoudt; Cedric Hermans; Omar Nyabi; Catherine Lombard; Mustapha Najimi; Etienne Sokal
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.